细胞减灭术和腹腔热化疗（CRS/HIPEC）是治疗腹腔转移瘤的复杂手术。术后加强恢复（ERAS）方案旨在标准化术前、术中和术后路径，以改善患者护理。本研究描述了在三级学术中心实施CRS/HIPEC ERAS方案后的可行性和结果。回顾了2020年1月至2023年3月的一所医疗机构的CRS/HIPEC经验。根据患者是否在ERAS开始前或后进行CRS/HIPEC进行分类。评估了结果和方案依从性。共纳入115例CRS /HIPEC手术，其中74例在ERAS实施前进行，41例在ERAS实施后进行。后ERAS组的中位年龄较年轻，而性别、合并症、腹腔癌指数、手术类型和手术时间在两组之间相似。最常见的原发癌部位是妇科（40%）、阑尾（24%）和结直肠（22%）。术后ERAS组件的依从性为76%。术后ERAS组在术后第1天行走（90% vs 54%；p < 0.001）、术后第2天耐受液体饮食（88% vs 32%；p < 0.001）和术后第3天拔除导尿管（86% vs 43%；p < 0.001）方面更多。后ERAS队列的住院时间有减少的趋势（7 vs 8天；p =0 .092），但重要并发症、重症监护室入住率和30天再入院率无差异。尽管CRS/HIPEC手术的异质性，但实施ERAS方案对我们的患者可行，并导致术后结果和依从性与其他重要腹部手术相当。这支持了为CRS/HIPEC患者实施ERAS方案的成功潜力。 © 2023年。外科肿瘤学会。

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) are complex operations for the treatment of peritoneal metastases. Enhanced recovery after surgery (ERAS) protocols are intended to standardize preoperative, intraoperative, and postoperative pathways, with the goal of improving patient care. This study describes feasibility and outcomes after implementing an ERAS protocol for CRS/HIPEC at a tertiary academic center.A single-institution experience of CRS/HIPEC was reviewed from January 2020 to March 2023. Patients were categorized according to whether they underwent CRS/HIPEC before or after ERAS initiation. Outcomes and protocol adherence were evaluated.A total of 115 CRS/HIPEC operations were included-74 before and 41 after ERAS implementation. Median age was younger in the post-ERAS group, whereas sex, comorbidities, peritoneal carcinomatosis index, operation performed, and operative time were similar between groups. The most common primary cancer sites were gynecologic (40%), appendiceal (24%), and colorectal (22%). Adherence to all postoperative ERAS components was 76%. More post-ERAS patients ambulated by postoperative day (POD) 1 (90% vs. 54%; p < 0.001), tolerated liquid diet by POD 2 (88% vs. 32%; p < 0.001), and had foley removed by POD 3 (86% vs. 43%; p < 0.001). There was a trend toward decreased length of stay in the post-ERAS cohort (7 vs. 8 days; p = 0.092), with no difference in major complications, intensive care unit admission, or 30-day readmission.Despite the heterogeneity of CRS/HIPEC operations, implementing an ERAS protocol for our patients was feasible and resulted in postoperative outcomes and adherence comparable with that of other major abdominal surgeries. This supports the potential for success in ERAS programs for CRS/HIPEC patients.© 2023. Society of Surgical Oncology.